NASDAQ:ASND - Ascendis Pharma A/S News Headlines

Sign in or create an account to add this stock to your watchlist.
$128.96 +4.31 (+3.46 %)
(As of 05/26/2019 09:50 AM ET)
Previous Close$128.96
Today's Range$124.57 - $129.64
52-Week Range$53.21 - $131.76
Volume189,769 shs
Average Volume352,337 shs
Market Capitalization$5.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Headlines

Ascendis Pharma A/S (NASDAQ ASND) News Headlines

Source:
DateHeadline
Short Interest in Ascendis Pharma A/S (ASND) Drops By 36.9%Short Interest in Ascendis Pharma A/S (ASND) Drops By 36.9%
www.americanbankingnews.com - May 26 at 3:23 AM
Ascendis Pharma A/S (ASND) Set to Announce Earnings on ThursdayAscendis Pharma A/S (ASND) Set to Announce Earnings on Thursday
www.americanbankingnews.com - May 23 at 1:29 AM
Ascendis Pharma A/S (ASND) Given a $219.00 Price Target at WedbushAscendis Pharma A/S (ASND) Given a $219.00 Price Target at Wedbush
www.americanbankingnews.com - May 20 at 9:01 PM
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth HormoneAscendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
finance.yahoo.com - May 20 at 12:32 PM
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
finance.yahoo.com - May 16 at 11:02 AM
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare ConferenceAscendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
finance.yahoo.com - May 7 at 6:02 PM
$660,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter$660,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - May 7 at 1:16 AM
What You Must Know About Ascendis Pharma A/Ss (NASDAQ:ASND) Financial HealthWhat You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
finance.yahoo.com - May 6 at 6:29 PM
What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial HealthWhat You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
finance.yahoo.com - May 6 at 6:29 PM
Ascendis Pharma A/S (ASND) Given Average Recommendation of "Buy" by AnalystsAscendis Pharma A/S (ASND) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 6 at 2:43 PM
 Brokerages Anticipate Ascendis Pharma A/S (ASND) to Announce -$0.97 Earnings Per Share Brokerages Anticipate Ascendis Pharma A/S (ASND) to Announce -$0.97 Earnings Per Share
www.americanbankingnews.com - May 6 at 12:11 AM
Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
finance.yahoo.com - April 29 at 5:46 PM
Glenview Capital Management’s Stock Pitches At 2018 Sohn ConferenceGlenview Capital Management’s Stock Pitches At 2018 Sohn Conference
finance.yahoo.com - April 27 at 9:35 AM
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical ConferencesAscendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
finance.yahoo.com - April 24 at 5:34 PM
Joseph Jolson’s Harvest Capital Strategies’ Return, AUM, and HoldingsJoseph Jolson’s Harvest Capital Strategies’ Return, AUM, and Holdings
finance.yahoo.com - April 23 at 9:30 AM
Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMTEdited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT
finance.yahoo.com - April 15 at 11:04 AM
What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?
finance.yahoo.com - April 11 at 10:47 AM
Ascendis Pharma A/S ASND price target raised to $133.00 by Canaccord GenuityAscendis Pharma A/S ASND price target raised to $133.00 by Canaccord Genuity
www.marketwatch.com - April 6 at 9:27 AM
Ascendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call TranscriptAscendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call Transcript
www.fool.com - April 4 at 2:15 AM
Ascendis Pharma A/S Reports Full Year 2018 Financial ResultsAscendis Pharma A/S Reports Full Year 2018 Financial Results
finance.yahoo.com - April 3 at 6:53 PM
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
www.nasdaq.com - March 27 at 6:28 PM
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
finance.yahoo.com - March 27 at 6:28 PM
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-LifeAscendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
www.globenewswire.com - March 25 at 6:21 PM
Ascendis Pharma A/S ASND has coverage initiated with a Outperform Outperform ratingAscendis Pharma A/S ASND has coverage initiated with a Outperform Outperform rating
www.marketwatch.com - March 25 at 6:21 PM
Ascendis Pharma reports positive data from phase 3 heiGHt trialAscendis Pharma reports positive data from phase 3 heiGHt trial
seekingalpha.com - March 25 at 9:07 AM
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable SafetyAscendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety
www.nasdaq.com - March 24 at 6:47 PM
Ascendis Pharma Announces Phase 3 heiGHt Trial...Ascendis Pharma Announces Phase 3 heiGHt Trial...
www.benzinga.com - March 24 at 6:47 PM
Ascendis Pharma - Its Been All About Growth... Ascendis Pharma - It's Been All About Growth...
www.rttnews.com - March 12 at 11:22 AM
What Makes Ascendis Pharma A/S (ASND) a New Buy StockWhat Makes Ascendis Pharma A/S (ASND) a New Buy Stock
www.zacks.com - March 12 at 10:45 AM
Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%
finance.yahoo.com - March 6 at 6:19 PM
Ascendis Pharma Prices 4.166M ADS Offering @$122/ADSAscendis Pharma Prices 4.166M ADS Offering @$122/ADS
finance.yahoo.com - March 6 at 9:42 AM
Ascendis Pharma launches equity offering; shares down 1% after hoursAscendis Pharma launches equity offering; shares down 1% after hours
seekingalpha.com - March 4 at 6:30 PM
BRIEF-Ascendis Pharma Says Once-Weekly Transcon Growth Hormone Demonstrated Superiority On Primary EndpointBRIEF-Ascendis Pharma Says Once-Weekly Transcon Growth Hormone Demonstrated Superiority On Primary Endpoint
www.msn.com - March 4 at 10:37 AM
Ascendis Pharma up 56% premarket on positive TransCon dataAscendis Pharma up 56% premarket on positive TransCon data
seekingalpha.com - March 4 at 10:37 AM
Why Ascendis Pharma Shares Hit an All-Time HighWhy Ascendis Pharma Shares Hit an All-Time High
247wallst.com - March 4 at 10:37 AM
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone DeficiencyAscendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
finance.yahoo.com - March 4 at 10:37 AM
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for AchondroplasiaAscendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
finance.yahoo.com - March 1 at 9:53 AM
Ascendis Pharma Files IND for Hypoparathyroidism CandidateAscendis Pharma Files IND for Hypoparathyroidism Candidate
www.zacks.com - February 13 at 9:43 AM
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with HypoparathyroidismAscendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
finance.yahoo.com - February 11 at 5:36 PM
Ascendis Pharma inks $200M stock sales deal with JPMorganAscendis Pharma inks $200M stock sales deal with JPMorgan
seekingalpha.com - February 9 at 5:01 PM
Ascendis Pharma (ASND) Shares Cross Below 200 DMAAscendis Pharma (ASND) Shares Cross Below 200 DMA
www.nasdaq.com - February 5 at 5:27 PM
All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to BuyAll You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy
www.zacks.com - January 25 at 9:27 AM
Cantor sees 40% upside in Ascendis Pharma in premarket analyst actionCantor sees 40% upside in Ascendis Pharma in premarket analyst action
seekingalpha.com - January 24 at 9:48 AM
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple ApproachesAscendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
finance.yahoo.com - January 7 at 9:19 AM
Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare ConferenceAscendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 4:43 PM
Should You Buy Ascendis Pharma A/S (ASND)?Should You Buy Ascendis Pharma A/S (ASND)?
finance.yahoo.com - December 12 at 4:52 PM
Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMTEdited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT
finance.yahoo.com - December 10 at 9:16 AM
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q3 2018 Results - Earnings Call TranscriptAscendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 29 at 9:51 AM
Ascendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call TranscriptAscendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript
www.fool.com - November 29 at 12:10 AM
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNPAscendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
finance.yahoo.com - November 28 at 4:40 PM
This page was last updated on 5/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel